For the year ending 2025-12-31, PGEN had $717K increase in cash & cash equivalents over the period. -$89,826K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -250,642 |
| Depreciation and amortization | 3,199 |
| Gain (loss) on disposals of assets, net | -14 |
| Impairment of goodwill | 3,907 |
| Impairment of other noncurrent assets | 0 |
| Gain on debt retirement | 0 |
| Loss on reclassification of cumulative foreign currency translation adjustments | 0 |
| Change in fair value of warrant liabilities | -139,523 |
| Amortization of discounts on investments, net | 2,205 |
| Stock-based compensation expense | 10,866 |
| Shares issued as payment for services | 527 |
| Accretion of debt discount and amortization of deferred financing costs | 356 |
| Total deferred tax (benefit) | 0 |
| Issuance cost related to warrants | 0 |
| Other noncash items | 0 |
| Trade | 2,990 |
| Other | 209 |
| Inventory | 9,209 |
| Prepaid expenses and other | 93 |
| Other assets | 556 |
| Accounts payable | 8,768 |
| Accrued compensation and benefits | 6,662 |
| Other accrued liabilities | 6,869 |
| Deferred revenue | -2,006 |
| Lease liabilities | -9 |
| Other long-term liabilities | 134 |
| Indemnification accruals | -737 |
| Net cash used in operating activities | -87,831 |
| Purchases of investments | 208,006 |
| Sales and maturities of investments | 208,466 |
| Purchases of property, plant and equipment | 1,995 |
| Proceeds from sale of assets | 0 |
| Net cash used in investing activities | -1,535 |
| (payments) proceeds from issuance of common stock, net of issuance costs | -355 |
| Proceeds from long-term debt, net of issuance costs | 92,818 |
| Payments of long-term debt, including cost to retire of 120 in 2023 | 0 |
| (payments) proceeds from issuance of series a preferred stock and warrants, net of issuance cost | -537 |
| Cash settlement of performance stock units | -1,304 |
| Payments to taxing authorities in connection with shares directly withheld from employees | 1,776 |
| Proceeds from stock option exercises | 1,202 |
| Net cash provided by financing activities | 90,048 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 35 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 717 |
| Beginning of year | 29,517 |
| End of year | 30,234 |
PRECIGEN, INC. (PGEN)
PRECIGEN, INC. (PGEN)